Journal article Open Access
Lenka D.N.; Routray S.N.
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd"> <identifier identifierType="DOI">10.5281/zenodo.3365128</identifier> <creators> <creator> <creatorName>Lenka D.N.</creatorName> <affiliation>Senior Resident, Dept. of Cardiology, S.C.B.Medical College. Cuttack, Odisha, India.</affiliation> </creator> <creator> <creatorName>Routray S.N.</creatorName> <affiliation>Professor, Dept. of Cardiology, S.C.B.Medical College. Cuttack, Odisha, India.</affiliation> </creator> </creators> <titles> <title>EFFICACY AND SAFETY OF AZILSARTAN COMPARED WITH TELMISARTAN IN HYPERTENSIVE PATIENTS.</title> </titles> <publisher>Zenodo</publisher> <publicationYear>2019</publicationYear> <subjects> <subject>Blood Pressure Azilsartan Telmisartan.</subject> </subjects> <dates> <date dateType="Issued">2019-07-01</date> </dates> <resourceType resourceTypeGeneral="Text">Journal article</resourceType> <alternateIdentifiers> <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/3365128</alternateIdentifier> </alternateIdentifiers> <relatedIdentifiers> <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.3365127</relatedIdentifier> </relatedIdentifiers> <rightsList> <rights rightsURI="http://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights> <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights> </rightsList> <descriptions> <description descriptionType="Abstract"><p>Objective: Angiotensive receptor blockers (ARBs) are very potent antihypertensive agents , Telmisartan being the prototype and most widely used.This study was undertaken to compare the efficacy and safety of Azilsartan a new ARB with Telmisartan. Material and methods : This prospective study was carried out in patients attending the Department of Medicine, SCB Medical college, Cuttack. Patients with newly diagnosed with stage I-II essential hypertension of either sex within the age group of 18?65 years with blood pressure of &ge;140/90 mmHg were included in the study. Severe hypertension &gt;180/110 mm of Hg, hypersensitivity to ARBs, secondary hypertension with any other etiology, pregnant women, history of Drug/ Alcohol abuse, cardiac arrhythmias were excluded. Patients who gave consent for the study were divided into 2 random groups 1 and 2 ? the first received azilsartan and the second received telmisartan. Point of control was defined as blood pressure&lt;140/90 mm of Hg after initiation of therapy. Results : 180 patients were randomized into two groups. Out of 90 patients included in group 1 who received azilsartan, 4 lost for follow up. Out of 90 patients included in group 2 who received telmisartan, 5 lost for follow up. There was no significant difference between the two drugs in both mean systolic and diastolic blood pressure at 24hrs, 1 month and 3 months and 6 months. Mean diastolic blood pressure at 24 hrs was reduced more with telmisartan compared to azilsartan which is significant. Hypotension related adverse effects occurred in 3% of the patients in azilsartan group while it occurred in 8% of them in telmisartan group. Conclusion: Azilsartan is an effective blood pressure lowering drug with its safety and efficacy comparable to that of telmisartan.</p></description> </descriptions> </resource>